Szu-Chun Yang

List of Publications by Year
in descending order

39	433	759233	794594
papers	citations	12 h-index	19 g-index

40	40	40	783
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Liquid biopsy genotyping in lung cancer: ready for clinical utility?. Oncotarget, 2017, 8, 18590-18608.	1.8	52
2	Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan. Lung Cancer, 2017, 108, 183-191.	2.0	49
3	Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879758.	3.2	41
4	Rasch models suggested the satisfactory psychometric properties of the World Health Organization Quality of Lifeâ€"Brief among lung cancer patients. Journal of Health Psychology, 2017, 22, 397-408.	2.3	37
5	The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. PLoS ONE, 2018, 13, e0192161.	2.5	26
6	Estimating the lifelong health impact and financial burdens of different types of lung cancer. BMC Cancer, 2013, 13, 579.	2.6	21
7	Estimation of loss of quality-adjusted life expectancy (QALE) for patients with operable versus inoperable lung cancer: Adjusting quality-of-life and lead-time bias for utility of surgery. Lung Cancer, 2014, 86, 96-101.	2.0	18
8	Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up. Journal of Thoracic Oncology, 2019, 14, 1892-1900.	1.1	16
9	Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice. Quality of Life Research, 2016, 25, 1441-1449.	3.1	15
10	Comparison of Global Initiative for Chronic Obstructive Pulmonary Disease 2013 Classification and Body Mass Index, Airflow Obstruction, Dyspnea, and Exacerbations Index in Predicting Mortality and Exacerbations in Elderly Adults with Chronic Obstructive Pulmonary Disease. Journal of the American Geriatrics Society, 2015, 63, 244-250.	2.6	14
11	Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. BMJ Open, 2020, 10, e033427.	1.9	14
12	Positive blood culture is not associated with increased mortality in patients with sepsisâ€induced acute respiratory distress syndrome. Respirology, 2013, 18, 1210-1216.	2.3	13
13	Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401875507.	3.2	13
14	Realâ€world outcomes of NSCLC patients receiving tissue or circulating tumor DNAâ€guided osimertinib treatment. Cancer Medicine, 2019, 8, 5939-5947.	2.8	12
15	Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports, 2021, 11, 12180.	3.3	11
16	Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. PLoS ONE, 2020, 15, e0231413.	2.5	10
17	Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. BMJ Open, 2019, 9, e022293.	1.9	9
18	EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. Journal of the Formosan Medical Association, 2021, 120, 1729-1739.	1.7	9

#	Article	IF	Citations
19	Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 760686.	2.8	8
20	The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy. Scientific Reports, 2022, 12, 3319.	3.3	7
21	Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment. Lung Cancer, 2021, 158, 137-145.	2.0	6
22	Life expectancy (LE) and loss-of-LE for patients with chronic obstructive pulmonary disease. Respiratory Medicine, 2020, 172, 106132.	2.9	5
23	QALYs and medical costs saved from prevention of a cancer: Analysis of nation-wide real-world data of Taiwan with lifetime horizon. Journal of the Formosan Medical Association, 2021, 120, 2089-2099.	1.7	5
24	Indigenous recurrent disseminated histoplasmosis in Taiwan. Journal of Microbiology, Immunology and Infection, 2020, 53, 1047-1049.	3.1	4
25	Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence Areas. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 774-782.e4.	4.9	4
26	Downstream Complications and Healthcare Expenditure after Invasive Procedures for Lung Lesions in Taiwan. International Journal of Environmental Research and Public Health, 2021, 18, 4040.	2.6	3
27	Improved survival in patients with unresectable stage <scp>III EGFR</scp>â€mutant adenocarcinoma with upfront <scp>EGFR</scp>â€tyrosine kinase inhibitors. Thoracic Cancer, 2022, 13, 182-189.	1.9	3
28	<scp> PM _{2.5} </scp> exposure and risk of lung adenocarcinoma in women of Taiwan: A caseâ€“control study with density sampling. Respirology, 0, , .	2.3	3
29	The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study. Frontiers in Oncology, 2021, 11, 671127.	2.8	2
30	Typical antipsychotics is associated with increased risk of severe exacerbation in asthma patients: a nationwide population-based cohort study. BMC Pulmonary Medicine, 2022, 22, 85.	2.0	2
31	Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008â€“2016. Journal of General Internal Medicine, 2021, 36, 3589-3591.	2.6	1
32	Germ Cell Tumor With Somatic-Type Malignancy Presenting As Right Facial Swelling in a Young Woman. Journal of Clinical Oncology, 2011, 29, e699-e701.	1.6	0
33	Diminishing marginal cost-effectiveness in risk-targeted lung cancer screening. Translational Cancer Research, 2018, 7, 1310-1312.	1.0	0
34	Title is missing!. , 2020, 15, e0231413.		0
35	Title is missing!. , 2020, 15, e0231413.		0
36	Title is missing!. , 2020, 15, e0231413.		0

#	Article	IF	Citations
37	Title is missing!. , 2020, 15, e0231413.		0
38	Title is missing!. , 2020, 15, e0231413.		0
39	Title is missing!. , 2020, 15, e0231413.		0